Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function

Agop Y. Bedikian, Jeffrey A. Silverman, Nicholas E. Papadopoulos, Kevin B. Kim, Anne E. Hagey, Anna Vardeleon, Wen Jen Hwu, Jade Homsi, Michael Davies, Patrick Hwu

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being developed for the systemic treatment of cancer. This study evaluated the pharmacokinetics (PK) of Marqibo in subjects with melanoma and impaired hepatic function. Calculated PK parameters were similar in subjects with impaired liver function compared with those in subjects with adequate liver function. Subjects with impaired liver function universally had a monoexponential total plasma VCR concentration versus time decline, whereas two thirds of subjects with adequate liver function had a biexponential decline profile. Because one third of subjects with normal hepatic function demonstrated monoexponential disposition, lack of biexponential disposition in the hepatically impaired subjects cannot be clearly attributed to liver impairment. VSLI was generally well tolerated in all subjects.

Original languageEnglish (US)
Pages (from-to)1205-1212
Number of pages8
JournalJournal of Clinical Pharmacology
Volume51
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

Vincristine
Liposomes
Pharmacokinetics
Safety
Injections
Liver
Neoplasms
Melanoma

Keywords

  • Clinical pharmacology
  • clinical research
  • oncology
  • pharmacokinetics and drug metabolism
  • pharmacology

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Bedikian, A. Y., Silverman, J. A., Papadopoulos, N. E., Kim, K. B., Hagey, A. E., Vardeleon, A., ... Hwu, P. (2011). Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. Journal of Clinical Pharmacology, 51(8), 1205-1212. https://doi.org/10.1177/0091270010381499

Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. / Bedikian, Agop Y.; Silverman, Jeffrey A.; Papadopoulos, Nicholas E.; Kim, Kevin B.; Hagey, Anne E.; Vardeleon, Anna; Hwu, Wen Jen; Homsi, Jade; Davies, Michael; Hwu, Patrick.

In: Journal of Clinical Pharmacology, Vol. 51, No. 8, 01.08.2011, p. 1205-1212.

Research output: Contribution to journalArticle

Bedikian, AY, Silverman, JA, Papadopoulos, NE, Kim, KB, Hagey, AE, Vardeleon, A, Hwu, WJ, Homsi, J, Davies, M & Hwu, P 2011, 'Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function', Journal of Clinical Pharmacology, vol. 51, no. 8, pp. 1205-1212. https://doi.org/10.1177/0091270010381499
Bedikian, Agop Y. ; Silverman, Jeffrey A. ; Papadopoulos, Nicholas E. ; Kim, Kevin B. ; Hagey, Anne E. ; Vardeleon, Anna ; Hwu, Wen Jen ; Homsi, Jade ; Davies, Michael ; Hwu, Patrick. / Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. In: Journal of Clinical Pharmacology. 2011 ; Vol. 51, No. 8. pp. 1205-1212.
@article{b5d0690f62164c2384eabd10ba590377,
title = "Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function",
abstract = "Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being developed for the systemic treatment of cancer. This study evaluated the pharmacokinetics (PK) of Marqibo in subjects with melanoma and impaired hepatic function. Calculated PK parameters were similar in subjects with impaired liver function compared with those in subjects with adequate liver function. Subjects with impaired liver function universally had a monoexponential total plasma VCR concentration versus time decline, whereas two thirds of subjects with adequate liver function had a biexponential decline profile. Because one third of subjects with normal hepatic function demonstrated monoexponential disposition, lack of biexponential disposition in the hepatically impaired subjects cannot be clearly attributed to liver impairment. VSLI was generally well tolerated in all subjects.",
keywords = "Clinical pharmacology, clinical research, oncology, pharmacokinetics and drug metabolism, pharmacology",
author = "Bedikian, {Agop Y.} and Silverman, {Jeffrey A.} and Papadopoulos, {Nicholas E.} and Kim, {Kevin B.} and Hagey, {Anne E.} and Anna Vardeleon and Hwu, {Wen Jen} and Jade Homsi and Michael Davies and Patrick Hwu",
year = "2011",
month = "8",
day = "1",
doi = "10.1177/0091270010381499",
language = "English (US)",
volume = "51",
pages = "1205--1212",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function

AU - Bedikian, Agop Y.

AU - Silverman, Jeffrey A.

AU - Papadopoulos, Nicholas E.

AU - Kim, Kevin B.

AU - Hagey, Anne E.

AU - Vardeleon, Anna

AU - Hwu, Wen Jen

AU - Homsi, Jade

AU - Davies, Michael

AU - Hwu, Patrick

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being developed for the systemic treatment of cancer. This study evaluated the pharmacokinetics (PK) of Marqibo in subjects with melanoma and impaired hepatic function. Calculated PK parameters were similar in subjects with impaired liver function compared with those in subjects with adequate liver function. Subjects with impaired liver function universally had a monoexponential total plasma VCR concentration versus time decline, whereas two thirds of subjects with adequate liver function had a biexponential decline profile. Because one third of subjects with normal hepatic function demonstrated monoexponential disposition, lack of biexponential disposition in the hepatically impaired subjects cannot be clearly attributed to liver impairment. VSLI was generally well tolerated in all subjects.

AB - Marqibo (vincristine sulfate liposome injection, VSLI) is a novel liposomal formulation of vincristine sulfate (VCR) being developed for the systemic treatment of cancer. This study evaluated the pharmacokinetics (PK) of Marqibo in subjects with melanoma and impaired hepatic function. Calculated PK parameters were similar in subjects with impaired liver function compared with those in subjects with adequate liver function. Subjects with impaired liver function universally had a monoexponential total plasma VCR concentration versus time decline, whereas two thirds of subjects with adequate liver function had a biexponential decline profile. Because one third of subjects with normal hepatic function demonstrated monoexponential disposition, lack of biexponential disposition in the hepatically impaired subjects cannot be clearly attributed to liver impairment. VSLI was generally well tolerated in all subjects.

KW - Clinical pharmacology

KW - clinical research

KW - oncology

KW - pharmacokinetics and drug metabolism

KW - pharmacology

UR - http://www.scopus.com/inward/record.url?scp=79960712418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960712418&partnerID=8YFLogxK

U2 - 10.1177/0091270010381499

DO - 10.1177/0091270010381499

M3 - Article

C2 - 20978276

AN - SCOPUS:79960712418

VL - 51

SP - 1205

EP - 1212

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8

ER -